A Phase 3 interventional study of Menostar (Estradiol, BAY86-5435) and Raloxifene in Osteopenia, sponsored by Bayer. Completed. Open to female participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-30.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this trial is to investigate whether the Menostar patch is as safe and effective in the prevention of bone loss in postmenopausal women as raloxifen, a drug already registered for prevention and treatment of osteoporosis.
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
This study's enrollment of 500 is above the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Browse Bone Diseases, Metabolic studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Menostar (Estradiol, BAY86-5435)
Drug: Raloxifene
Drug pages: Estradiol · Ethinyl Estradiol
Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
Raloxifene tbl. (60 mg/day)
Percentage change in Bone Mineral Density at the lumbar spine
Time frame: after 3 years
Percentage change in Bone Mineral Density of the hip
Time frame: after 3 years
Percentage change in biochemical markers of bone turnover
Time frame: after 6 months
Proportion of patients with hot flushes
Time frame: after 3 year
Change in Women's Health Questionnaire
Time frame: after 2 years
Proportion of patients with an abnormal endometrial biopsy
Time frame: after 3 years
Pharmacogenetic analysis
Time frame: after 2 years
Digital breast density analysis
Time frame: after 2 years
No study locations are listed for this record.
The record gives a start of Feb 2004 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Ethinyl Estradiol